Dr. Mechoulam’s latest discovery is called EPM301, or cannabidiolic acid methyl ester, also known as CBDa. EPM stands for Endless Potential Molecules, and there are now around 14 patented molecules that are being tested on humans with the US FDAs guidance. The first targets of EPM are psoriasis and inflammatory bowel disease (IBD), which are notoriously difficult to treat.
A new collaboration brings together iconic functional glass, carefully selected cannabis genetics and a mission…
This interview by Micah Johnson originally appeared in High Times Local, produced under license by…
Congress's watchdog confirmed the DEA has no complete written procedures for drug scheduling. Learn why…
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…